Tempus AI, Inc.
Financials
Valuation Metrics
Tempus AI, Inc.'s Market Cap is $14.43B. At end of 2025 it was $10.29B. Ranked #731 of 3,121 in US market (top 23%), #230 of 1,463 on NASDAQ (top 16%), #47 of 205 in Health Care Equipment & Services (top 23%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.43B | US#731/3,121 Sec#47/205 |
| Revenue | $1.43B | US#1,661/3,121 Sec#102/205 |
| Net Income | $-254M | US—/3,121 Sec—/205 |
| Total Assets | $2.37B | US#1,973/3,121 Sec#94/205 |
| Net Assets | $445M | US#2,310/3,121 Sec#122/205 |
| Employees | 3,800 | US#1,371/3,121 Sec#97/205 |
| Value | ||
| P/B | 32.43x | US#2,855/3,121 Sec#185/205 |
| P/S | 10.08x | US#2,689/3,121 Sec#184/205 |
| FCF Yield | -1.89% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -57.18% | US#2,710/3,121 Sec#172/205 |
| ROA | -10.75% | US#2,676/3,121 Sec#156/205 |
| Op. Margin | -19.76% | US#2,606/3,121 Sec#165/205 |
| Revenue Growth | 50.43% | US#224/3,121 Sec#12/205 |
| Financial Health | ||
| Debt Ratio | 431.74% | US#2,308/3,121 Sec#179/205 |
| Total Debt | $1.44B | US#1,353/3,121 Sec#69/205 |
| FCF | $-273M | US#2,838/3,121 Sec#201/205 |
| Cash | $600M | US#956/3,121 Sec#50/205 |
| Current Ratio | 3.30x | US#709/3,121 Sec#72/205 |
| Performance | ||
| 1Y Return | -7.04% | US#2,027/3,121 Sec#140/205 |
| 1M Return | 62.80% | US#10/3,121 Sec#2/205 |
| From 52W High | -22.97% | US#1,687/3,121 Sec#117/205 |
| 1Y MDD | -59.76% | US#2,773/3,121 Sec#172/205 |
| Trading | ||
| Volume | 16,635,814 shares | US#90/3,121 Sec#3/205 |
| Trading Value | $1.30B | US#59/3,121 Sec#2/205 |
| Per Share | ||
| EPS | $-1.42 | US—/3,121 Sec—/205 |
| BPS | $2.48 | US#2,545/3,121 Sec#167/205 |
Company Info
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.